

31-year-old Kris Carr documents her experience with epithelioid hemangioendothelioma, a rare cancer, while seeking alternative treatments and support from others.
Synopsis
31-year-old Kris Carr documents her experience with epithelioid hemangioendothelioma, a rare cancer, while seeking alternative treatments and support from others.
People
Synopsis
Kris Carr learns she has epithelioid hemangioendothelioma (EHE) after months of believing her symptoms were due to a yoga injury. At 31, she documents her experiences after her diagnosis in 2007. Carr consults multiple oncologists, including Dr. George Demetri at the Dana-Farber Cancer Institute, and rejects a proposed organ transplant. She adopts a vegan diet and participates in a healing program at the Hippocrates Health Institute in Florida. The film includes interviews with other young women living with cancer.
Deep Dive
Why Watch
- Meet Kris Carr and her unique cancer approach.
- Find out about alternative treatments like yoga and acupuncture.
- See how diet changes impact cancer recovery.
Did You Know
- Kris Carr premiered Crazy Sexy Cancer on March 11, 2007, at SXSW.
- The film aired on TLC on August 29, 2007.
- Carr adopted a vegan diet, incorporating foods like leafy greens and wheatgrass.
- Carr consulted Dr. George Demetri at the Dana–Farber Cancer Institute.
- The film has a duration of 90 minutes.
Perfect For
Frequently Asked Questions
When did Crazy Sexy Cancer premiere?
Crazy Sexy Cancer premiered on March 11, 2007, at the South by Southwest (SXSW) Film Festival.
What type of cancer was Kris Carr diagnosed with?
Kris Carr was diagnosed with epithelioid hemangioendothelioma (EHE), a rare form of cancer.
What dietary changes did Kris Carr make during her treatment?
Kris Carr adopted a vegan diet, incorporating foods such as leafy greens, vegetables, sprouted grains, nuts, seeds, and various juices.
What are people saying?
Play More Like This
Where else to watch
Browse more like this
Related Films
Is this your film?
If you made this film or hold the rights to it, we'd like to talk. We can license it and pay you a share of what it earns.






























Comments